Section 01
What it's used for
Approved for Child Growth Failure
FDA-approved (as Geref) for children with growth failure from unexplained GH deficiency. A clinical review confirms sustained gains in growth speed and normalized IGF-1 levels, though exact growth-rate figures were not given.
▸Clinical wording
Sermorelin (Geref) was FDA-approved for treatment of idiopathic growth hormone deficiency in children with growth failure. A clinical review confirms sustained increases in growth velocity and normalization of IGF-1 levels in GH-deficient children treated with sermorelin, though specific growth-velocity figures for sermorelin itself are not established in the available literature.
Studied for Adult GH Decline
Used in anti-aging and wellness medicine for the age-related drop in growth hormone. Its drug class has been studied in older adults for body composition, sleep, and thinking, but data are sparse, with none specific to this peptide.
▸Clinical wording
Sermorelin is used in anti-aging and wellness medicine to address age-related decline in growth hormone secretion. GHRH-class secretagogues as a group have been studied in older adults for effects on body composition, sleep, and cognition, but the literature explicitly notes a paucity of data on the clinical effects of these compounds, and no sermorelin-specific trial data on lean body mass, GH pulsatility, or skin thickness was found.
Used to Test Pituitary Function
Used diagnostically (as Geref Diagnostic) to test the pituitary gland's ability to release growth hormone, often combined with arginine — an established test method. No publication supports pinpointing a pituitary vs. hypothalamic problem.
▸Clinical wording
Sermorelin (Geref Diagnostic) has been used diagnostically to evaluate pituitary growth hormone secretory capacity. GHRH-based stimulation testing, commonly performed with a combined GHRH-arginine protocol, is an established clinical method for assessing GH secretion, but no publication was found supporting the specific claim that a blunted response indicates pituitary-level dysfunction while a normal response with reduced spontaneous GH indicates hypothalamic-level deficiency.
Improves Deep Sleep Signal
Given before bedtime, it boosts the body's nighttime surge of growth hormone. Research shows longer deep sleep, better sleep efficiency, and improved self-reported sleep quality, linked to stronger hormone release during dreamless sleep.
▸Clinical wording
Sermorelin administered before bedtime amplifies the physiological nocturnal GH surge. Research shows improvements in slow-wave (deep) sleep duration, sleep efficiency, and subjective sleep quality — effects directly linked to enhanced GH pulsatility during NREM sleep.
Unproven Cognitive Claim
Vendor and community sources describe it as supporting brain function in aging via growth hormone and IGF-1, but no study backs this claim for this peptide. The one controlled trial showing a benefit used tesamorelin, a related peptide.
▸Clinical wording
Vendor and community material describes sermorelin as supporting cognitive function in aging through GH and IGF-1 effects on neuronal survival and synaptic plasticity, but no published study was found behind this claim for sermorelin specifically. The one relevant controlled human trial showing cognitive benefit in older adults and patients with mild cognitive impairment used tesamorelin, a different GHRH analog, not sermorelin.
Section 02
Mechanism of Action
Pressing the pituitary's growth hormone button
- Sermorelin binds the receptor for growth-hormone-releasing hormone on the pituitary cells that store it.
- Binding raises an internal messenger (cAMP) that activates an enzyme opening calcium channels.
- The combined messenger and calcium signal drives both hormone production and release of stored granules.
▸Clinical wording
GHRH Receptor Agonism
Sermorelin binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells, activating Gαs-coupled adenylyl cyclase. The resulting increase in intracellular cAMP activates PKA, which phosphorylates voltage-gated calcium channels and promotes calcium influx. This dual cAMP/calcium signaling drives both GH gene transcription and GH granule exocytosis.
Keeping the body's natural rhythm
- Sermorelin triggers growth hormone in the natural pulses the body already uses.
- Dosing before bed amplifies the night-time pulse, the largest natural surge of the day.
- Keeping that pulsing pattern maintains receptor sensitivity and gives more natural downstream hormone levels.
▸Clinical wording
Physiological GH Release
Sermorelin stimulates GH release that follows natural pulsatile patterns. Administration before bedtime amplifies the nocturnal GH pulse — the largest physiological GH surge of the day. This preservation of pulsatile dynamics maintains GH receptor sensitivity and produces more physiological IGF-1 levels compared to exogenous GH.
Feeding the hormone-producing cells themselves
- Beyond triggering release, sermorelin has growth-promoting effects on the pituitary cells that make the hormone.
- Ongoing stimulation is said to maintain the number of those cells and their output capacity.
- This may counteract the shrinkage of those cells that comes with ageing.
- The source states only that effects may persist after stopping, not that they do.
▸Clinical wording
Somatotroph Trophic Effects
Beyond acute GH release, sermorelin has trophic (growth-promoting) effects on somatotroph cells themselves. Chronic GHRH receptor stimulation maintains somatotroph cell mass and secretory capacity, potentially counteracting the somatotroph atrophy associated with aging. This trophic effect means sermorelin's benefits may persist even after discontinuation.
The body's own brakes stay intact
- Unlike injected growth hormone, sermorelin leaves the normal brain-pituitary feedback loops working.
- A braking hormone, somatostatin, continues to regulate the pulses of growth hormone.
- Negative feedback from the downstream growth factor prevents excessive hormone output.
- The source calls this self-limiting design a key safety advantage.
▸Clinical wording
Preserved Feedback Mechanisms
Unlike exogenous GH, sermorelin preserves all normal hypothalamic-pituitary feedback loops. Somatostatin continues to regulate GH pulses, and IGF-1 negative feedback prevents excessive GH production. This self-limiting mechanism is a key safety advantage.
What the released hormone does next
- The released growth hormone switches on a liver pathway producing a growth factor (IGF-1).
- It also acts directly on fat tissue to break down stored fat.
- In skeletal muscle the hormone drives protein-building effects known as anabolic.
▸Clinical wording
Downstream GH Signaling
Sermorelin-stimulated GH release activates the full spectrum of GH-dependent pathways: JAK2/STAT5-mediated hepatic IGF-1 production, direct GH-mediated lipolysis in adipose tissue, and protein anabolic effects in skeletal muscle.
Section 03
Biological Pathways
- GHRH-R / cAMP / PKA / CREBGHRH receptor activation raises cAMP via adenylyl cyclase; PKA phosphorylates CREB, which binds CRE elements to drive GH gene transcription, and also phosphorylates Pit-1, enhancing its binding to the GH promoter.
- Calcium/Calmodulin (CaMK) PathwayPKA-mediated phosphorylation of L-type calcium channels increases calcium influx; calcium binds calmodulin to activate CaMK, contributing to GH granule exocytosis and somatotroph gene expression.
- GH/IGF-1/mTOR AxisReleased GH activates hepatic JAK2/STAT5 signaling to produce IGF-1, which engages its receptor tyrosine kinase and activates PI3K/Akt/mTOR, the central pathway for protein synthesis and cell growth.
- Somatotroph Trophic MaintenanceChronic GHRH-R stimulation engages Ras/Raf/MEK/ERK signaling in somatotrophs, promoting cell survival and proliferation that maintains pituitary somatotroph mass and secretory capacity.
- Preserved Hypothalamic FeedbackUnlike exogenous GH, sermorelin preserves feedback loops: somatostatin continues regulating GH pulses and IGF-1 negative feedback limits output, a self-limiting mechanism absent with direct GH dosing.
Section 04
Dosage Information
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Subcutaneous — children's label | Geref label, growth hormone deficiency in children | 30 µg/kg once daily at bedtime — about 0.9 mg for a 30 kg child. 110 children were dosed; 56 could be judged at 12 months | Growth sped up, but less than with somatropin at the same 30 µg/kg; final adult height was never checked. Off the market since 2008, with no label. |
| Intravenous — diagnostic test | Geref Diagnostic label, growth-hormone reserve test | 1 µg/kg in one injection — 70–90 µg for a 70–90 kg adult | A test dose, given once to read the growth-hormone spike that follows — not a regimen, and about a third of what is injected nightly in practice. |
| Subcutaneous — trial in adults 55–71 | Placebo-controlled trial, adults aged 55–71, 16 weeks | 10 µg/kg nightly — 0.7–0.9 mg for a 70–90 kg adult; 19 people took part | The growth marker IGF-I rose in two weeks and slid back by week 16. Muscle grew in men only, skin in both, bone density did not move. At triple the usual dose. |
| Subcutaneous — trial in men 64–76 | Healthy men aged 64–76, six weeks | 2 mg nightly — roughly 22–29 µg/kg for a 70–90 kg adult; eleven men who started with low IGF-I | Night growth hormone nearly doubled, yet IGF-I and its carriers did not move. Seven to ten times the pharmacy dose; one shot a night was judged too few. |
| Subcutaneous — self-administration | Compounded product, self-administration outside any trial | Pharmacy monographs say 0.2–0.3 mg nightly; guides circulate 0.5–2 mg, five to seven nights a week — roughly 2–29 µg/kg for 70–90 kg | What is sold is a compounded or research-grade preparation no regulator has reviewed, not Geref. The tenfold spread stands because no adult dose study exists. |
| Intranasal | Nasal sprays sold now; one 8-child pilot in research | No dose is established. Only 3–5% reaches the blood through the nose, so matching the intravenous dose took 30 to 100 times as much | The one child pilot lost its effect in six months, brought antibodies and nose irritation, and was judged unsuitable. Sprays are sold with no human dose. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
- Protocol 01
Sermorelin Anti-Aging Protocol
Natural GH stimulation for anti-aging, recovery, and body composition. Physician-guided protocol.
- Focus
- Anti-Aging
- Level
- Beginner
- Duration
- 6+ months
Section 06
Stability & Storage
Lyophilised powder
Sermorelin acetate is supplied as a lyophilised white powder, kept at −20°C for long-term stability (up to 24 months) or at 2-8°C for 3-6 months, protected from light and moisture. The peptide carries a methionine residue at position 27 that is prone to oxidation, so research formulations sometimes add antioxidant stabilisers such as sodium bisulfite or extra methionine.
After reconstitution
It is reconstituted with bacteriostatic water using gentle swirling rather than vigorous shaking, giving a clear, colourless solution. Store at 2-8°C and use within 14-21 days, keeping air exposure to the vial to a minimum since the methionine residue oxidises readily.
Section 07
Side Effects & Precautions
Most reported effects with sermorelin are mild, transient, and injection-related; fluid retention in particular is described as milder than with exogenous growth hormone because sermorelin works through the body's own release mechanism.
Injection Site Reactions
The most common adverse effect is mild pain, redness, or swelling at the injection site. These reactions are generally mild and transient.
Flushing, Headache, and Dizziness After Injection
- Facial flushing: warmth and redness of the face can appear within minutes of injection and last 5-15 minutes, from sermorelin's mild vasodilatory effect; harmless.
- Headache: mild headaches have been reported, particularly during the initial days of treatment, typically resolving with continued use.
- Dizziness: transient lightheadedness may occur shortly after injection.
Water Retention
Mild fluid retention is possible from GH-mediated sodium and water retention. This effect is generally milder than with exogenous GH, because sermorelin-stimulated GH release is physiological.
Hyperactivity in Children
In pediatric patients, transient hyperactivity has been reported. This is generally self-limiting and does not require discontinuation.
Self-Limiting GH Release, Decades of Use
Sermorelin has one of the best-characterized safety profiles among GH-related peptides, supported by decades of clinical use. Its GH release is self-limiting because the body's somatostatin feedback stays intact, which caps excess GH.
Section 08
Regulatory Status
The agency approved sermorelin acetate under the brand Geref for diagnosing growth hormone deficiency and for treating pediatric GH deficiency; the manufacturer withdrew the branded product in 2008 for business reasons, not safety. What is sold as «sermorelin» today comes from compounding pharmacies, not from an approved manufacturing line.
FDA / United States
Approved as Geref, later withdrawn
Sermorelin acetate was approved as Geref for diagnosing GH deficiency in adults and for treating pediatric idiopathic GH deficiency. EMD Serono pulled the injectable from the US market in 2008 for commercial reasons, not a safety finding.
Compounding pharmacies
Available today only through compounding
There is no FDA-approved sermorelin product on the market. What pharmacies dispense under this name is prepared under section 503A or 503B by prescription, from bulk sermorelin acetate — a different regulatory track from an approved drug.
WADA
Prohibited under category S2
The WADA Prohibited List names sermorelin explicitly as a GHRH analogue in section S2.2.4, alongside CJC-1295 and tesamorelin. The ban applies to every competing athlete, in and out of competition, with no exemption for a past approval history.
Regulatory status is not the same thing everywhere and it is not fixed: a prior FDA approval, an active compounding market and a WADA ban can all be true about the same molecule at once. Check the current rules in your own country and sport before relying on any of this.
Section 09
Research Studies
- [1]Growth hormone-releasing hormone receptor (GHRH-R) and its signalingHalmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. · Reviews in Endocrine and Metabolic Disorders · 2025
- [2]Structural basis for activation of the growth hormone-releasing hormone receptorZhou F, Zhang H, Cong Z, Zhao LH, Zhou Q, Mao C, et al. · Nature Communications · 2020
- [3]Regulation of the pituitary somatotroph cell by GHRH and its receptorMayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. · Recent Progress in Hormone Research · 2000
- [4]Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controlsSteiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. · Neuroendocrinology · 1992
- [5]Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administrationSchier T, Guldner J, Colla M, Holsboer F, Steiger A. · Journal of Neuroendocrinology · 1997
- [6]Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly menVittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, et al. · Metabolism · 1997
- [7]Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old menCorpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. · The Journal of Clinical Endocrinology & Metabolism · 1992
- [8]Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and womenKhorram O, Laughlin GA, Yen SS. · The Journal of Clinical Endocrinology & Metabolism · 1997
- [9]Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?Walker RF. · Clinical Interventions in Aging · 2006
- [10]Activation of Male Liver Chromatin Accessibility and STAT5-Dependent Gene Transcription by Plasma Growth Hormone PulsesConnerney J, Lau-Corona D, Rampersaud A, Waxman DJ. · Endocrinology · 2017
Section 10
Frequently Asked Questions
The human trial record is mixed rather than clearly positive. In adults aged 55–71, IGF-1 rose within two weeks but slid back toward baseline by week 16 despite continued dosing, muscle grew only in the men, and bone density did not change; in men aged 64–76, nightly growth hormone output nearly doubled, yet IGF-1 itself did not move. A review of GHRH-class secretagogues in older adults explicitly notes a paucity of data, and no sermorelin-specific trial on lean mass, GH pulsing or skin thickness was found.
Bedtime dosing is designed to amplify the largest natural growth-hormone pulse of the day, which occurs during deep sleep. In the trial that measured this, IGF-1 was already elevated at two weeks but had faded by week 16 while dosing continued — no study has established a stable, lasting timeline for its effects.
Sermorelin was FDA-approved as Geref for diagnosing GH deficiency and treating it in children, but the manufacturer voluntarily withdrew the product from the US market in 2008 for commercial reasons, not safety. It remains available only through compounding pharmacies today, with no FDA-approved product currently on the market. WADA prohibits it under the S2 category for growth hormone-releasing factors, banned both in and out of competition.
Pharmacy compounding monographs describe 0.2–0.3 mg nightly, while online guides circulate 0.5–2 mg, five to seven nights a week — a roughly tenfold spread. Neither figure comes from a human dose-finding study, because none has ever been conducted for adult use; the clinical trials that do exist used doses three to ten times higher, for research purposes only.
This has not been studied directly. The closest available data point is that in the 16-week adult trial, the IGF-1 rise seen at two weeks had already faded by the end of the study while dosing was still ongoing, suggesting the effect does not simply persist — but no trial has followed people after discontinuation to measure what changes.
Reported effects include facial flushing lasting 5–15 minutes after injection, mild injection-site pain or redness, occasional headache and dizziness, and mild water retention from GH-mediated sodium retention. In children, transient hyperactivity has been reported. Decades of clinical use, including its original FDA approval trials, back a generally favorable safety record.
The lyophilised powder is stable at −20°C for up to 24 months or at 2–8°C for 3–6 months, protected from light and moisture because a methionine residue is prone to oxidation. Once reconstituted with bacteriostatic water, it is kept at 2–8°C and used within 14–21 days.